ПАЦИЕНТ С ТРАНСПЛАНТИРОВАННЫМ СЕРДЦЕМ

Литература

79.Nomura S., Yoshimura K., Akiyama N. et al. HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins // Eur. Surg. Res. 2005. Vol. 37. Р. 370–378.

80.Pham S.M., Kormos R.L., Kawai A. et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience // Transplant. Proc. 1996. Vol. 28. Р. 1002–1004.

81.Poon M., Marx S.O., Gallo R. et al. Rapamycin inhibits vascular smooth muscle cell migration // J. Clin. Invest. 1996. Vol. 98. Р. 2277–2283.

82.Poston R.S., Billingham M., Hoyt E.G. et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model // Circulation. 1999. Vol. 100.

Р.67–74.

83.Raichlin E., Bae J.-H., Khalpey Z. et al. Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation // Circulation. 2007. Vol. 116. Р. 2726–2733.

84.Reisin E., Weir M., Falkner B. et al. Lisinopril Versus Hydrochlorothiazide in Obese Hypertensive Patients // Hypertension. 1997. Vol. 30. Р. 140–145.

85.Repp K.L. еt al. Drug-related problems and hospital admissions in cardiac transplant recipients // Ann. Pharmacother. 2012. Vol. 46 (10). Р. 1299–1307.

86.Rubin R. Infection in the organ transplant recipient // Rubin RHYL, ed. Clinical Approach to Infection in the Compromised Host. 3rd ed. New York, NY: Plenum; 2003.

87.Rustad L.A. еt al. One year of high-intensity interval training improves exercise capacity, but not left ventricular function in stable heart transplant recipients: A randomised controlled trial European Journal of Preventive Cardiology. 2014. Vol. 21. Р. 181–191.

88.Schroeder J.S., Gao S.Z., Alderman E.L. et al. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. // N. Engl. J. Med. 1993. Vol. 328. Р. 164–170.

89.Schwaiger M., Hutchins G.D., Kalff V. et al. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography // J. Clin. Invest.1991. Vol. 87. Р. 1681–1690.

90.See Jr. V.Y., DeNofrio D., Goldberg L. et al. Effect of atorvastatin on post-cardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction // Am. J. Cardiol. 2003. Vol. 92. Р. 11–15.

91.Shaddy R.E., Hammond E.H., Yowell R.L. Immunohistochemical analysis of plate- let-derived growth factor and basic fibroblast growth factor in cardiac biopsy and autopsy specimens of heart transplant patients // Am. J. Cardiol. 1996. Vol. 77.

Р.1210–1215.

92.Shane E., Mancini D., Aaronson K. et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure // Am. J. Med. 1997. Vol. 103.

Р.197–207.

93.Shaw S.M., Chaggar P., Ritchie J. et al. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporine // Transplantation. 2009. Vol. 87. Р. 771–775.

141

С.В. ГОТЬЕ, А.О. ШЕВЧЕНКО, В.Н. ПОПЦОВ

94.Shirakawa I., Sata M., Saiura A. et al. Atorvastatin attenuates transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation // Biomed Pharmacother. 2007. Vol. 61. Р. 154–159.

95.Simon G. Pathogenesis of structural vascular changes in hypertension // J. Hypertens. 2004. Vol. 22 (1). Р. 3–10.

96.Sipahi I., Nicholls S.J., Tuzcu E.M., Nissen S.E. Coronary atherosclerosis can regress with very intensive statin therapy // Cleve Clin. J. Med. 2006. Vol. 73. Р. 937–944.

97.Sirolimus Immunoprophylaxis and Renal Histological Changes in Long-Term Cardiac Transplant Recipients: A Pilot Study Ann Pharmacother. 2014. Vol. 48.

Р.837–846.

98.Soave R. Prophylaxis strategies for solid-organ transplantation // Clin. Infect. Dis. 2001. Vol. 33 (Suppl. 1). Р. S26–S31.

99.Stark R.P., McGinn A.L., Wilson R.F. Chest pain in cardiac-transplant recipients. Evidence of sensory reinnervation after cardiac transplantation // N. Engl. J. Med. 1991. Vol. 324. Р. 1791–1794.

100.Starling R.C., Cody R.J. Cardiac transplant hypertension // Am. J. Cardiol. 1990. Vol. 65. Р. 106–111.

101.Stehlik J. et al. The Registry of the International Society for Heart and Lung Transplantation: 29th Official Adult Heart Transplant Report-2012 // J. Heart. Lung. Transplant. 2012. Vol. 31 (10). Р. 1052–1064.

102.Stein W., Schrepfwer S., Iton S. et al. Prevention of transplant coronary artery disease by prenylation inhibitors // J. Heart. Lung. Transplant. 2011. Vol. 30.

Р.761–769.

103.Stojanovic I., Vrtovec B., Radovancevic B. et al. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year fol- low-up // J. Heart. Lung. Transplant. 2005. Vol. 24. Р. 1235–1238.

104.Sulemanjee N.Z. еt al. The First Year Post-Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications // J. Cardiovasc. Pharmacol. Ther. 2008. Vol. 13. Р. 13–31.

105.Suzuki J., Isobe M., Kawauchi M. еt al. Altered expression of matrix metalloproteinases and tissue inhibitors of metal-loproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates // Transplant. Int. 2000. Vol. 13. Р. 106–113.

106.Taylor D.O., Barr M.L., Meiser B.M. et al. Suggested guidelines for the use of tacrolimus in cardiac transplant recipients // J. Heart. Lung. Transplant. 2001. Vol. 20.

Р.734–738.

107.Taylor D.O., Bristow M.R., O’Connell J.B. et al. Improved long-term survival after heart transplantation predicted by successful early withdrawal from maintenance corticosteroid therapy // J. Heart. Lung. Transplant. 1996. Vol. 15. Р. 1039–1046.

108.Taylor D.O., Edwards L.B., Mohacsi P.J. et al. The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report—2003 // J. Heart. Lung. Transplant. 2003. Vol. 22. Р. 616–624.

109.Tona F., Marra M.P., Fedrigo M. et al. Recent developments on coronary microvasculopathy after heart transplantation: a new target in the therapy of cardiac allograft vasculopathy // Curr. Vasc. Pharmacol. 2012. Vol. 10 (2). Р. 206–215.

142

Литература

110.Tortorice K.L., Heim-Duthoy K.L. et al. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients // Ther. Drug. Monit. 1990. Vol. 12. Р. 321–328.

111.Uretsky B.F., Shaver J.A., Liang C.S. et al. Modulation of hemodynamic effects with a converting enzyme inhibitor: acute hemodynamic dose-response relationship of a new angiotensin converting enzyme inhibitor, lisinopril, with observations on long-term clinical, functional, and biochemical responses // Am. Heart. J. 1988. Vol. 116. Р. 480–488.

112.Verani M.S., Nishimura S., Mahmarian J.J. et al. Cardiac function after orthotopic heart transplantation: response to postural changes, exercise, and beta-adrener- gic blockade // J. Heart. Lung. Transplant. 1994. Vol. 13. Р. 181–193.

113.Wallace C.K., Stetson S.J., Kucuker S.A. et al. Simvastatin decreases myocar-dial tumor necrosis factor alpha content in heart transplant recipients // J. Heart. Lung. Transplant. 2005. Vol. 24. Р. 46–51.

114.Weis M., Pehlivanli S., Meiser B.M., von Scheidt W. Simvastatin treatment is associated with improvement in coronary endothelial function and decreased cytokine activation in patients after heart transplantation // J. Am. Coll. Cardiol. 2001. Vol. 38. Р. 814–818.

115.Wenke K., Meiser B., Thiery J. et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial // Circulation. 1997. Vol. 96. Р. 1398–1402.

116.Wenke K., Meiser B., Thiery J. et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience // Circulation. 2003. Vol. 107. Р. 93–97.

117.Wenke K., Meiser B., Thiery J., Reichart B. Impact of simvastatin therapy after heart transplantation: an 11-year prospective evaluation // Herz. 2005. Vol. 30. Р. 431– 432.

118.White M., Boucher A., Dandavino R. et al. Sirolimus Immunoprophylaxis and Renal Histological Changes in Long-Term Cardiac Transplant Recipients. A Pilot Study // Ann. Pharmacother. 2014. Vol. 48 (7). Р. 837–846.

119.Wilson R.F., Christensen B.V., Olivari M.T. et al. Evidence for structural sympathetic reinnervation after orthotopic cardiac transplantation in humans // Circulation. 1991. Vol. 83. Р. 1210–1220.

120.Wu A.H., Ballantyne C.M., Short B.C. et al. Statin use and risks of death or fatal rejection in the Heart Transplant Lipid Registry // Am. J. Cardiol. 2005. Vol. 95.

143

Готье С.В., Шевченко А.О., Попцов В.Н.

ПАЦИЕНТ С ТРАНСПЛАНТИРОВАННЫМ

СЕРДЦЕМ

Руководство для врачей по ведению пациентов, перенесших

трансплантацию сердца

Подписано к печати . .2014 г.

Формат 70×100 1/16. Усл. печ. л. 9. Бумага мелованная. Печать офсетная. Гарнитура GaramondC. Тираж 1000 экз.

ООО «Издательство «Триада». ИД № 06059 от 16.10.01 г.

170034, г. Тверь, пр. Чайковского, д. 9, оф. 504, тел./факс [phone], 354130 E-mail: [e-mail]

Заказ

Отпечатано в соответствии с предоставленными материалами в ЗАО «ИПК Парето-Принт», г. Тверь

www.pareto-print.ru